 |
|
Nonalcoholic fatty liver disease and non-liver comorbidities
Richie Manikat, Mindie H. Nguyen
Clin Mol Hepatol. 2023;29(Suppl):s86-s102. Published online 2023 Jan 5 DOI: https://doi.org/10.3350/cmh.2022.0442
|
|
Citations to this article as recorded by
 Adverse pregnancy outcomes as a risk factor for new-onset metabolic dysfunction-associated steatotic liver disease in postpartum women: A nationwide study
Young Mi Jung, Seung Mi Lee, Wonyoung Wi, Min-Jeong Oh, Joong Shin Park, Geum Joon Cho, Won Kim
JHEP Reports.2024; 6(4): 101033. CrossRef Type 2 diabetes mellitus and cardiometabolic outcomes in metabolic dysfunction-associated steatotic liver disease population
Nicholas W.S. Chew, Xin Hui Pan, Bryan Chong, Chanchal Chandramouli, Mark Muthiah, Carolyn S.P. Lam
Diabetes Research and Clinical Practice.2024; 211: 111652. CrossRef Comorbidities and Malignancy among NAFLD Patients Compared to the General Population, A Nation-Based Study
Naim Abu-Freha, Bracha Cohen, Michal Gordon, Sarah Weissmann, Alexander Fich, Daniela Munteanu, David Yardeni, Ohad Etzion
Biomedicines.2023; 11(4): 1110. CrossRef Implications of comorbidities in nonalcoholic fatty liver disease
Sherlot Juan Song, Vincent Wai-Sun Wong
Clinical and Molecular Hepatology.2023; 29(2): 384. CrossRef Discovery of tetrasubstituted thiophenes as Cisd2 activators: A potential novel therapeutic option in nonalcoholic fatty liver disease
Chun-Hsu Yao, Zhao-Qing Shen, Yesudoss Christu Rajan, Yu-Wen Huang, Chin-Yu Lin, Jen-Shin Song, Hui-Yi Shiao, Yi-Yu Ke, Yu-Shiou Fan, Chi-Hui Tsai, Teng-Kuang Yeh, Ting-Fen Tsai, Jinq-Chyi Lee
European Journal of Medicinal Chemistry.2023; 258: 115583. CrossRef Letter regarding “Non-alcoholic fatty liver disease: Definition and subtypes”
Seogsong Jeong, Yohwan Lim, Su Kyoung Lee, Hyun Wook Han
Clinical and Molecular Hepatology.2023; 29(3): 810. CrossRef Raspberry ketone ameliorates nonalcoholic fatty liver disease in rats by activating the AMPK pathway
Mervat E. Askar, Sousou I. Ali, Nahla N. Younis, Mohamed A. Shaheen, Mahmoud E. Zaher
European Journal of Pharmacology.2023; 957: 176001. CrossRef The Efficacy of Anthropometric Indicators in Predicting Non-Alcoholic Fatty Liver Disease Using FibroScan® CAP Values among the Taiwanese Population
Meng-Szu Lee, Eva Belingon Felipe-Dimog, Jeng-Fu Yang, Yi-Yu Chen, Kuan-Ta Wu, Hsiang-Ju Kuo, Tzu-Chun Lin, Chao-Ling Wang, Meng-Hsuan Hsieh, Chia-Yi Lin, Batbold Batsaikhan, Chi-Kung Ho, Ming-Tsang Wu, Chia-Yen Dai
Biomedicines.2023; 11(9): 2518. CrossRef New Insights into the Pathogenesis of Metabolic-Associated Fatty Liver Disease (MAFLD): Gut–Liver–Heart Crosstalk
Keungmo Yang, Myeongjun Song
Nutrients.2023; 15(18): 3970. CrossRef
|